BACKGROUND AND AIMS: Our understanding of the long-term safety of prenatal exposure to opioid maintenance treatment (OMT) is insufficient. We compared childhood morbidity (0-3 years) between OMT-exposed and relevant comparison groups. DESIGN: Nation-wide, registry-based cohort study. Registries on reproductive health, addiction treatment, hospitalization and death were linked using identification numbers. SETTING: The Czech Republic (2000-14). PARTICIPANTS: Children with different prenatal exposure: (i) mother in OMT during pregnancy (OMT; n = 218), (ii) mother discontinued OMT before pregnancy (OMT-D; n = 55), (iii) mother with opioid use disorder, but not in OMT during pregnancy (OUD; n = 85) and (iv) mother in the general population (GP) (n = 1 238 452) MEASUREMENTS: Episodes of hospitalization were observed as outcomes. Information on in-patient contacts, length of stay and diagnoses (International Classification of Diseases version 10) were assessed. Binary logistic regressions were conducted to estimate the associations between OMT exposure and the outcomes, crude and adjusted for the socio-economic status and smoking. FINDINGS: No significant differences were found in the overall proportion of hospitalization among OMT-exposed children, children of OMT-D and children of women with OUD [54.1%, 95% confidence interval (CI) = 47.3-60.1%; 47.3%, 95% CI = 33.9-61.1%; 51.8%, 95% CI = 40.7%-62.6%], while the proportion was significantly lower (35.8%, 95% CI = 35.7-35.8%) in the GP. There were no significant differences in risk of specific diagnoses between OMT-exposed children, children of OMT-D and children of women with OUD. In the adjusted analyses, differences between OMT-exposed and children in the GP were still present for infections and parasitic diseases (OR = 2.0, 95% CI = 1.4-2.7), diseases of the digestive system (OR = 1.7, 95% CI = 1.2-2.6) and diseases of the skin and subcutaneous tissue (OR = 1.9, 95% CI = 1.2-3.2). CONCLUSION: This study did not find clear evidence for an increase in risk of morbidity during the first 3 years of life in children with prenatal opioid maintenance treatment exposure compared with children of women who discontinued such treatment before pregnancy or suffered from opioid use disorder without this treatment. Compared the general population, there appears to be an increased risk of hospitalizations for infectious, gastrointestinal and skin diseases.

Department of Addictology 1st Faculty of Medicine Charles University Czech Republic

Institute of Health Information and Statistics of the Czech Republic

National Monitoring Centre for Drugs and Addiction Prague Czech Republic

Norwegian Centre for Addiction Research at the University of Oslo Norway

Norwegian institute of Public Health Oslo Norway

Zobrazit více v PubMed

World Health Organization (WHO) . Guidelines for Identification and Management of Substance Use and Substance Use Disorders in Pregnancy. Geneva: WHO; 2014. PubMed

Farid W. O., Dunlop S. A., Tait R. J., Hulse G. K. The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data. Curr Neuropharmacol 2008; 6: 125–150. PubMed PMC

Jones H. E., O'Grady K. E., Malfi D., Tuten M. Methadone maintenance vs. methadone taper during pregnancy: maternal and neonatal outcomes. Am J Addict 2008; 17: 372–386. PubMed

Norgaard M., Nielsson M. S., Heide‐Jorgensen U. Birth and neonatal outcomes following opioid use in pregnancy: a Danish population‐based study. Subst Abuse Res Treat 2015; 9: 5–11. PubMed PMC

Hunt R. W., Tzioumi D., Collins E., Jeffery H. E. Adverse neurodevelopmental outcome of infants exposed to opiate in‐utero . Early Hum Dev 2008; 84: 29–35. PubMed

Kaltenbach K., O'Grady K. E., Heil S. H., Salisbury A. L., Coyle M. G., Fischer G. et al Prenatal exposure to methadone or buprenorphine: early childhood developmental outcomes. Drug Alcohol Depend 2018; 185: 40–49. PubMed PMC

Konijnenberg C., Melinder A. Prenatal exposure to methadone and buprenorphine: a review of the potential effects on cognitive development. Child Neuropsychol 2011; 17: 495–519. PubMed

Konijnenberg C., Sarfi M., Melinder A. Mother–child interaction and cognitive development in children prenatally exposed to methadone or buprenorphine. Early Hum Dev 2016; 101: 91–97. PubMed

Kivisto K., Tupola S., Kivitie‐Kallio S. Prenatally buprenorphine‐exposed children: health to 3 years of age. Eur J Pediatr 2015; 174: 1525–1533. PubMed

Kelty E., Hulse G. A retrospective cohort study of the health of children prenatally exposed to methadone, buprenorphine or naltrexone compared with non‐exposed control children. Am J Addict 2017; 26: 845–851. PubMed

Kelly L. E., Rieder M. J., Bridgman‐Acker K., Lauwers A., Madadi P., Koren G. Are infants exposed to methadone in utero at an increased risk for mortality? J Popul Ther Clin Pharm 2012; 19: e160–e165. PubMed

Gomez‐Pomar E., Finnegan L. P. The epidemic of neonatal abstinence syndrome, historical references of its origins, assessment, and management. Front Pediatr 2018; 6: 33. PubMed PMC

Lind J. N., Petersen E. E., Lederer P. A., Phillips‐Bell G. S., Perrine C. G., Li R. et al Infant and maternal characteristics in neonatal abstinence syndrome—selected hospitals in Florida, 2010–2011. Morb Mortal Wkly Rep 2015; 64: 213–216. PubMed PMC

Patrick S. W., Burke J. F., Biel T. J., Auger K. A., Goyal N. K., Cooper W. O. Risk of hospital readmission among infants with neonatal abstinence syndrome. Hospital Pediatr 2015; 5: 513–519. PubMed PMC

Uebel H., Wright I. M., Burns L., Hilder L., Bajuk B., Breen C. et al Reasons for rehospitalization in children who had neonatal abstinence syndrome. Pediatrics 2015; 136: e811–e820. PubMed

Witt C. E., Rudd K. E., Bhatraju P., Rivara F. P., Hawes S. E., Weiss N. S. Neonatal abstinence syndrome and early childhood morbidity and mortality in Washington state: a retrospective cohort study. J Perinatol 2017; 37: 1124–1129. PubMed PMC

Gabrhelik R, Nechanska B, Mravcik V, Skurtveit S, Lund IO, Handal M. A unique opportunity to study short and long term consequences in children prenatally exposed to illicit drugs and opioid maintenance treatment using Czech and Scandinavian registers. Cent Eur J Public Health 2016;24:248–251. PubMed

Nechanska B., Mravcik V., Skurtveit S., Lund I. O., Gabrhelik R., Engeland A. et al Neonatal outcomes after fetal exposure to methadone and buprenorphine: national registry studies from the Czech Republic and Norway. Addiction 2018; 113: 1286–1294. PubMed PMC

Popov P. Metadonová substituční léčba v České republice [in Czech; Methadone substitution treatment in the Czech Republic]. Adiktologie 2002; 2: 25–31.

Vollset S. E. Confidence intervals for a binomial proportion. Stat Med 1993; 12: 809–824. PubMed

Al‐Hashimi M., Scott S. W., Thompson J. P. et al Opioids and immune modulation: more questions than answers. Br J Anaesth 2013; 111: 80–88. 10.1093/bja/aet153 PubMed DOI

Liang X., Liu R., Chen C., Ji F., Li T. Opioid system modulates the immune function: a review. Transl Perioper Pain Med 2016; 1: 5–13. PubMed PMC

Loomans E. M., van Dijk A. E., Vrijkotte T. G., van Eijsden M., Stronks K., Gemke R. J. et al Psychosocial stress during pregnancy is related to adverse birth outcomes: results from a large multi‐ethnic community‐based birth cohort. Eur J Public Health 2013; 23: 485–491. PubMed

Premji S. Perinatal distress in women in low‐ and middle‐income countries: allostatic load as a framework to examine the effect of perinatal distress on preterm birth and infant health. Matern Child Health J 2014; 18: 2393–2407. PubMed PMC

Fernandez S., Bruni T., Bishop D. V., Turuba R., Olibris B., Jumah N. A. Differences in hospital length of stay between neonates exposed to buprenorphine versus methadone in utero: a retrospective chart review. Paediatrics & Child Health 2017; 22: e22–e22. PubMed PMC

Morbidity through 3 Years of Age in Children of Women Using Methamphetamine during Pregnancy: A National Registry Study

Cannabis Use during Pregnancy and Risk of Adverse Birth Outcomes: A Longitudinal Cohort Study

Opioid maintenance treatment in the Czech Republic, Norway and Denmark: a study protocol of a comparative registry linkage study